394 related articles for article (PubMed ID: 12177686)
1. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
Lilienfeld S
CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
[TBL] [Abstract][Full Text] [Related]
2. Current status and new developments with galantamine in the treatment of Alzheimer's disease.
Tariot P
Expert Opin Pharmacother; 2001 Dec; 2(12):2027-49. PubMed ID: 11825333
[TBL] [Abstract][Full Text] [Related]
3. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
4. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
5. Galantamine: a review of its use in Alzheimer's disease.
Scott LJ; Goa KL
Drugs; 2000 Nov; 60(5):1095-122. PubMed ID: 11129124
[TBL] [Abstract][Full Text] [Related]
6. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
7. Galantamine for Alzheimer's disease and mild cognitive impairment.
Loy C; Schneider L
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
[TBL] [Abstract][Full Text] [Related]
8. Galantamine hydrobromide: an agent for Alzheimer's disease.
Zarotsky V; Sramek JJ; Cutler NR
Am J Health Syst Pharm; 2003 Mar; 60(5):446-52. PubMed ID: 12635450
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of galantamine.
Farlow MR
Clin Pharmacokinet; 2003; 42(15):1383-92. PubMed ID: 14674789
[TBL] [Abstract][Full Text] [Related]
10. Galantamine for Alzheimer's disease.
Loy C; Schneider L
Cochrane Database Syst Rev; 2004 Oct; (4):CD001747. PubMed ID: 15495017
[TBL] [Abstract][Full Text] [Related]
11. An update on the pharmacology of galantamine.
Villarroya M; García AG; Marco-Contelles J; López MG
Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
[TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease.
Dengiz AN; Kershaw P
CNS Spectr; 2004 May; 9(5):377-92. PubMed ID: 15115951
[TBL] [Abstract][Full Text] [Related]
13. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
14. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).
Maelicke A
Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923
[TBL] [Abstract][Full Text] [Related]
15. Galantamine in Alzheimer's disease.
Razay G; Wilcock GK
Expert Rev Neurother; 2008 Jan; 8(1):9-17. PubMed ID: 18088197
[TBL] [Abstract][Full Text] [Related]
16. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
17. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
18. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
Aronson S; Van Baelen B; Kavanagh S; Schwalen S
Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
[TBL] [Abstract][Full Text] [Related]
19. The effects of galantamine treatment on caregiver time in Alzheimer's disease.
Sano M; Wilcock GK; van Baelen B; Kavanagh S
Int J Geriatr Psychiatry; 2003 Oct; 18(10):942-50. PubMed ID: 14533127
[TBL] [Abstract][Full Text] [Related]
20. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
